Sarcopenic Obesity: Why Resistance Training and Protein Lead, and How to Think About Peptides

Sarcopenic obesity is the coexistence of low skeletal-muscle mass and strength (sarcopenia) with excess body fat (obesity). It is especially relevant now because powerful GLP-1 and dual-agonist medications produce large, rapid weight loss, and a meaningful fraction of that loss can be lean mass — so preserving muscle during weight loss has become a central goal, not an afterthought. The evidence-based foundation is not a peptide: progressive resistance (strength) training is the most effective way to preserve and build muscle during a calorie deficit, and adequate dietary protein spread across the day supports muscle protein synthesis. Enough total energy quality, vitamin D and general nutrition, treating underlying conditions, and a rate of weight loss that isn't excessively fast all help protect lean tissue. If a weight-loss medication is used, it should be under a clinician, paired deliberately with strength training and protein to steer loss toward fat rather than muscle. Where do peptides enter? Mostly as speculative, unproven adjuncts. Growth-hormone secretagogues (like ipamorelin or CJC-1295) and other 'anabolic' peptides are promoted for muscle, and there is a general rationale that GH/IGF-1 signaling influences body composition, but they are research-grade, not approved for sarcopenic obesity, and lack controlled human evidence for it — and the GH axis has its own metabolic effects (including on glucose) that matter in this population. Follistatin-pathway agents targeting myostatin are experimental. The honest framing is that muscle is protected mainly by how you train, eat, and lose weight — with peptides an unproven sideline, not the core of the stack.